{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:32:20Z","timestamp":1792701140803,"version":"4.5.0"},"reference-count":25,"publisher":"SAGE Publications","issue":"1-2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Eur J Mass Spectrom (Chichester)"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:p>Ganciclovir (GCV) is an antiviral drug used to treat cytomegalovirus infections associated with AIDS. The study of the GCV drug substance under photo-oxidation stress conditions identified five impurities. This study aims to interpret the chemical structures of the photo-oxidation products using quadrupole time-of-flight (Q-TOF) mass spectrometry. An optimized chromatographic technique employing reverse-phase high-performance liquid chromatography with photodiode array detection was used to identify the degradation products of GCV. This technique utilized an Endurus Phenyl-hexyl HP column with an eluent mixture of acetonitrile, methanol, and 1\u2005M ammonium formate (pH 3.2). GCV's photo-oxidation products were effectively separated, achieving a resolution higher than 2.0. The Q-TOF mass spectrometry analysis characterized the five degradation products, which included 8-Oxo GCV, secondary degradation of 8-Oxo GCV, guanine, and one dehydrogenated compound. These new impurities require special attention because the drug's potency and impurity levels significantly influence the quality, safety, and effectiveness of pharmaceutical products.<\/jats:p>","DOI":"10.1177\/14690667261433458","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T10:24:52Z","timestamp":1775039092000},"page":"30-40","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Identification and characterization of unknown photo-oxidation degradation components of ganciclovir by high-performance liquid chromatography and quadrupole time-of-flight mass spectrometry"],"prefix":"10.1177","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-7774-2332","authenticated-orcid":false,"given":"Srikanth","family":"Pinapala","sequence":"first","affiliation":[{"name":"Technology and Research"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bangaraiah","family":"Pagala","sequence":"additional","affiliation":[{"name":"Technology and Research"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9539-2382","authenticated-orcid":false,"given":"Kumarswamy","family":"Ummiti","sequence":"additional","affiliation":[{"name":"College of Engineering, Koneru Lakshmaiah Education Foundation"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000925"},{"key":"e_1_3_3_3_2","unstructured":"CYTOVENE-IV (ganciclovir sodium) for injection for intravenous use. U.S. Food and Drug Administration Silver Spring. 2017 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/019661s036lbl.pdf (accessed 08 August 2025)."},{"key":"e_1_3_3_4_2","unstructured":"ZIRGAN- ganciclovir gel. U.S. Food and Drug Administration Silver Spring. 2024 https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=ea25e7ac-7a93-4ec8-975b-2cec197e1c27 (accessed 10 August 2025)."},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.5731\/pdajpst.2014.00974"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.2174\/1573412914666181024150632"},{"key":"e_1_3_3_7_2","unstructured":"Impurities in new drug products Q3B(R2). ICH harmonised tripartite guideline. 2006 https:\/\/database.ich.org\/sites\/default\/files\/Q3B%28R2%29%20Guideline.pdf (accessed 20 August 2025)."},{"key":"e_1_3_3_8_2","unstructured":"Office of Pharmaceutical Quality. Establishing Impurity Acceptance Criteria as Part of Specifications for NDAs ANDAs and BLAs Based on Clinical Relevance. Manual of Policies and Procedures; MAPP 5017.2 Rev. 1. 2020 https:\/\/www.fda.gov\/media\/124859\/download. (accessed 29 August 2025)."},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1080\/10826076.2013.836712"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/chromsci\/bmv029"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/jaoacint\/qsae057"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1177\/14690667251328804"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1177\/14690667211005335"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.4236\/ajac.2016.711073"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.2174\/1573412911666150519000155"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/sscp.70031"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.2174\/0115734110324919240918112907"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/sscp.70118"},{"key":"e_1_3_3_19_2","first-page":"4191","article-title":"Determination of assay and validation of stability indicating RP-HPLC method for Ganciclovir in nciclovir drug substance","volume":"9","author":"Madhusudhan P","year":"2020","unstructured":"Madhusudhan P, Venkateshwar RK, Surinderpal S. Determination of assay and validation of stability indicating RP-HPLC method for Ganciclovir in nciclovir drug substance. Int J Sci Technol Res 2020; 9: 4191\u20134195. https:\/\/www.ijstr.org\/final-print\/feb2020\/Determination-Of-Assay-And-Validation-Of-Stability-Indicating-Rp-hplc-Method-For-Ganciclovir-In-Nciclovir-Drug-Substance.pdf. accessed 21 July 2025.","journal-title":"Int J Sci Technol Res"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.5402\/2012\/894965"},{"key":"e_1_3_3_21_2","first-page":"1047","article-title":"New analytical method development and validation of ganciclovir by RP-HPLC and UV method along with forced degradation study","volume":"03","author":"Narendra BC","year":"2021","unstructured":"Narendra BC, Pooja SJ, Nitin VC. New analytical method development and validation of ganciclovir by RP-HPLC and UV method along with forced degradation study. Int Res J Modern Eng Technol Sci 2021; 03: 1047\u20131063. https:\/\/www.researchgate.net\/publication\/351658483_NEW_ANLYATICAL_METHOD_DEVELOPMENT_AND_VALIDATION_OF_GANCICLOVIR_BY_RP-HPLC_AND_UV_METHOD_ALONG_WITH_FORCED_DEGREDATION_STUDY. (accessed 24 July 2025).","journal-title":"Int Res J Modern Eng Technol Sci"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15010208"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.17145\/jab.18.022"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1186\/s41021-017-0081-0"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1080\/09553002.2021.2003464"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1015809408908"}],"container-title":["European Journal of Mass Spectrometry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/14690667261433458","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/14690667261433458","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/14690667261433458","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T20:04:45Z","timestamp":1777406685000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/14690667261433458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":25,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1177\/14690667261433458"],"URL":"https:\/\/doi.org\/10.1177\/14690667261433458","relation":{},"ISSN":["1469-0667","1751-6838"],"issn-type":[{"value":"1469-0667","type":"print"},{"value":"1751-6838","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]}}}